LATEST ALERTS
The passage of the 2018 Farm Bill removed hemp and compounds derived from hemp (including CBD) from the CSA. Therefore, the DEA should have very little involvement in enforcing laws and regulations on hemp and CBD
The US Food and Drug Administration (FDA) is a critical agency in the regulatory scheme of CBD products. The 2018 Farm Bill, which legalised hemp and CBD derived from it, granted the FDA the authority to regulate hemp products
Among the most important obligations delegated to it in the Farm Bill, the USDA is responsible for rule making regarding production and testing of hemp and approving state and tribal plans for hemp production
The company of the president of the European Industrial Hemp Association (EIHA) has challenged a ban on the sale of all foods containing CBD
A ministerial decree listing oral administration of CBD as a medicine under Italy’s Narcotics Law is meant to clear the way for the introduction of Epidyolex into the market, not to prevent consumer wellness products being sold
Our host for today’s podcast is Jon Bruford, a copy editor at CBD-Intel, who will be joined by CBD-Intel market analyst Maria Alejandra Estanga, who analyses the CBD market for European and American countries. In CBD-Intel’s new podcast, Alejandra discusses global CBD markets and their commonalities and differences, analysing each market and its own peculiarities based on regulations, market development » Continue Reading.
The National Advertising Division (NAD) of the US Better Business Bureau has referred advertising claims made by a CBD company to the Federal Trade Commission (FTC)
This week’s regulatory news in brief includes updates from the EU, Belgium, France, Germany, Italy Switzerland, the UK, Canada, Mexico, the US, Argentina, Australia, Israel, New Zealand, Nigeria, Rwanda, South Africa and Ukraine
It’s important to remember that all aspects of cannabis and CBD – even federal decriminalisation or legalisation efforts
CBD is listed on the Controlled Drug Register in Australia, which means it cannot be sold as a consumer product. This report offers an overview of the current regulatory framework in the country for CBD
This week’s regulatory news in brief includes updates from the EU, Austria, France Germany, Italy, the Netherlands, Slovakia, Romania, Spain, the UK, the US, Australia, Colombia, Israel, Lebanon, New Zealand, Russia and Ukraine
A Costa Rican bill legalising the production of hemp and medical cannabis looks likely to pass due to broad support from the ruling coalition and president
There are still quite a few unanswered questions regarding the novel food application process under the FSA. Fortunately the requirement of having toxicological data
Commercial interest in mushrooms as active ingredients is on the rise – despite legal issues that severely curtail commercial opportunities
A recent proposal in Brazil could see the legalisation of hemp cultivation for industrial purposes and cannabis for medical use. This report provides an overview of the current regulatory framework
This report takes a state-by-state look at the status of CBD in foods in the US, detailing the current framework and status
This week’s regulatory news in brief includes updates from Austria, Belgium, Germany, France, Italy, Switzerland, UK, the US, Mexico, Australia, Colombia, Costa Rica, Uruguay and Israel
The Zimbabwean agriculture minister has officially published a new statutory instrument to regulate the production, procurement, distribution, possession, sale, provision and transportation of industrial hemp
There has been increased interest in secondary markets that has resulted in some positive developments.
A proposal to be voted on by Brazilian legislators in the coming weeks could legalise the growing of hemp for industrial purposes and cannabis for medical use
This week’s regulatory news in brief includes updates from Spain, the UK, the US, Hong Kong, South Africa and Zimbabwe
The Marijuana Opportunity Reinvestment and Expungement (MORE) Act was, of course, always more about cannabis than hemp-derived CBD specifically. And, as previously stated, its chances of passing were slim to none.
There does not seem to be much point in continuing to try to force through bills – particularly given that the Republican-controlled senate and presidency opposes any measures and the limited timeframe before the end of the legislative session.
This week’s regulatory news in brief includes updates from France, Italy, Poland, Sweden, the US, the British Virgin Islands, Argentina, Australia, Ecuador, Israel, the Philippines and Russia
This regulatory report covers all aspects of the regulatory regime for hemp and CBD in Japan, including medical cannabis and import/export laws
This week’s regulatory news in brief includes updates from Czech Republic, France, Germany, Ireland, Lithuania, Malta, Netherlands, Slovakia, Ukraine, the UK, the US, Colombia, Israel and Russia
The US House of Representatives is expected to hold a historic vote this month on a comprehensive cannabis reform bill that supporters embrace for not only decriminalising marijuana but correcting injustices
What should the industry make of the recent paper from 11 industry associations putting forward a unified position on the issues surrounding the potential for CBD to be considered a narcotic? A
More than a dozen CBD businesses have given their backing to an investigation of the impact of CBD on liver toxicity levels in order to provide regulatory authorities in the US with reliable new data
Israel is considering amending the Dangerous Drugs Ordinance, which – if successful – will have a major impact on the market with hemp and CBD products
This week’s regulatory news in brief includes updates from Belgium, Germany, Malta, Canada, the US, Brazil, Chile, Colombia, Indonesia, Israel, New Zealand, Pakistan, Paraguay and Peru
First it’s important to note that the DEA proposals are only in a draft form and are open to comment until 20th October. They have already received a large number of comments, the majority of which appear to be criticising aspects of the proposed regulatory regime that have raised hackles among the industry.
Companies seeking licences to produce hemp in the Chinese province of Yunnan face a tightening of the application process, according to some who have successfully negotiated the concealed hurdles
The pharmaceutical side of the cannabinoid industry continues to grow, with several major announcements expanding treatments and blurring boundaries
CBD-Intel managing director, Tim Phillips, discusses the main facts and issues surrounding CBD and Novel Food status in European markets. He presents the key aspects of the delay, the political issues and the impacts released on the European level and the future challenges for the sector.
Proposed regulations from the US Drug Enforcement Administration (DEA) have riled the hemp and CBD sectors, with opinions divided on what the rule would mean if enacted in its current form
FOR IMMEDIATE RELEASE CBD food products to remain illegal for three years New report from CBD-Intel explores issues surrounding CBD as a novel food Don’t expect to see legal CBD food and drink products before 2023 at the very earliest, a new report from CBD-Intel warns. The use of CBD as a food ingredient has been on hold since European » Continue Reading.
This week’s regulatory news in brief includes updates from the Czech Republic, Sweden, Mexico, the US, Ecuador and Israel
The immediate impact of the decision is a reduction in certainty for CBD firms – not something they need at a time of significantly heightened uncertainty in other areas.
Do not expect European novel food authorisations before the end of 2022 at the very earliest and do not expect generic authorisations to cover non-applicant products, a new report from CBD-Intel warns
Charlotte’s Web has been denied a US trademark on appeal – a ruling that has serious implications for any company in the CBD sector selling food, drink or dietary supplement products in the US
A German company is still waiting to hear from the authorities two months after launching new CBD products that could be considered food supplements
This week’s regulatory news in brief brings updates from France, Germany, Poland, the UK, Canada, Mexico, the US, Argentina, Brazil, Israel, New Zealand, South Africa and Uruguay
Canopy, the Canadian cannabinoid company, has continued to commit heavily to BioSteel, a sports nutrition company in which Canopy now owns the majority share.
A group of tobacco retailers have written to the Italian Tobacconists Federation (FIT) asking it to push for a state monopoly on the sale of CBD flowers
Switzerland plans to launch trials next year as part of a move toward legalising cannabis with high levels of THC – but it could be several years before Swiss users can legally light up a joint
This week’s regulatory news in brief brings updates from Czech Republic, Cyprus, France, Germany, Italy, Switzerland, Canada, Mexico, the US, Israel, Panama, Paraguay, South Africa and Uruguay
The opinion (which is not yet set by the EC but appears to be the way the organisation is thinking) is based on a literal reading of the 1961 UN Narcotics Convention.
Clinical research guidance from the US Food and Drug Administration (FDA) should provide further impetus for cannabis research, which is certain to have an impact on the CBD market
This week’s regulatory news in brief brings updates from the EU, Czech Republic, Germany, Lithuania, Netherlands, Portugal, Canada, Mexico, the US, China, Colombia, Israel, Thailand and Uruguay
Stay up-to-date with key market trends and regulatory news and receive complimentary data on a regular basis.
"*" indicates required fields
Get 7 days of access to industry updates through our news analysis and regulatory alerts
"*" indicates required fields
Notifications
